With one of the largest life sciences practices in the U.S., Wilson Sonsini’s industry legacy dates to the formative years of biotech and medical device. Working closely with scientists and entrepreneurs who grew their companies into thriving businesses, we have worked alongside to support their endeavors from whiteboard to clinical trial and beyond.
Industry Highlights
Celebrating our founders’successes
2024
USANA Health Sciences on Acquisition of Hiya Health
Nutritional Supplements, Functional Foods and Personal Care Products
2024
LaNova Medicines on Exclusive Global License with Merck
Biotechnology
2024
Borealis Biosciences Announces $150 Million Series A and Strategic Collaboration Funding
RNA Medicines
2023
DTx Pharma Announces Acquisition by Novartis
Biotechnology
2023
Aspect Biosystems Announces $2.7 Billion Collaboration with Novo Nordisk
Biotechnology
2023
Chroma Medicine Lands $135 Million Series B Financing
Genomics
2022
Arcellx, Inc. Raises $124 Million IPO
Biotechnology
2021
Ventyx Biosciences Closes IPO at $175 Million
Biotechnology, Pharmaceuticals
2021
Tenaya Therapeutics Completes IPO Worth $207 Million
Biotechnology
2021
Kinnate Biopharma Raises $276 Million IPO
Drug Discovery, Pharmaceuticals
2020
Seer IPO Raises $175 Million in Nasdaq Debut
Decision / Risk Analysis
2020
PMV Pharmaceuticals Joins Nasdaq with $211 Million IPO
Drug Discovery
2020
Athira Pharma Closes $204 Million IPO
Drug Discovery
2020
ALX Oncology Prices IPO at $161 Million
Immuno-Oncology
2020
Applied Molecular Transport Closes IPO at $154 Million
Pharmaceuticals
2020
Oric Pharmaceuticals IPO Raises $120 Million
Drug Discovery
2019
Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination